https://www.globenewswire.com/news-release/2020/08/04/2072405/0/en/Resverlogix-Announces-Publication-on-Apabetalone-in-Cardiovascular-Therapeutics.html

Obviously good news, but you do get the impression RVX sometimes puts more effort into "academic" work at the expense of more urgent commercial priorities.